Platelet Phenotype Analysis of COVID-19 Patients Reveals Progressive Changes in the Activation of Integrin αIIbβ3, F13A1, the SARS-CoV-2 Target EIF4A1 and Annexin A5
Huriye Ercan, Waltraud C. Schrottmaier, Anita Pirabe, Anna Schmuckenschlager, David Pereyra, Jonas Santol, Erich Pawelka, Marianna Traugott, Christian Schörgenhofer, Tamara Seitz, Mario Karolyi, Jae‐Won Yang, Bernd Jilma, Alexander Zoufaly, Alice Assinger, Maria Zellner
Abstract
Platelets from COVID-19 patients showed significant changes in the activation phenotype, in the processing of the final coagulation factor F13A1 and the phospholipid-binding protein ANXA5 compared to healthy subjects. Additionally, these results demonstrate specific alterations in platelets during COVID-19, which are significantly linked to fatal outcome.
Topics & Concepts
PlateletMedicinePlatelet activationAnnexin A5AnnexinImmunologyPathogenesisFlow cytometryFactor XIIIAnnexin A2ThrombosisInternal medicineFibrinGastroenterologyCOVID-19 Clinical Research StudiesPlatelet Disorders and TreatmentsPhagocytosis and Immune Regulation